JP2016501876A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501876A5 JP2016501876A5 JP2015545458A JP2015545458A JP2016501876A5 JP 2016501876 A5 JP2016501876 A5 JP 2016501876A5 JP 2015545458 A JP2015545458 A JP 2015545458A JP 2015545458 A JP2015545458 A JP 2015545458A JP 2016501876 A5 JP2016501876 A5 JP 2016501876A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- pharmaceutical composition
- subject
- steroid
- seizure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003431 steroids Chemical class 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 20
- 206010010904 Convulsion Diseases 0.000 claims description 16
- AURFZBICLPNKBZ-FZCSVUEKSA-N 3beta-hydroxy-5alpha-pregnan-20-one Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-FZCSVUEKSA-N 0.000 claims description 13
- AURFZBICLPNKBZ-UHFFFAOYSA-N Pregnanolone Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 AURFZBICLPNKBZ-UHFFFAOYSA-N 0.000 claims description 13
- 206010015037 epilepsy Diseases 0.000 claims description 13
- 229920000858 Cyclodextrin Polymers 0.000 claims description 11
- 208000024891 symptom Diseases 0.000 claims description 10
- -1 alphadrone Chemical compound 0.000 claims description 8
- DUHUCHOQIDJXAT-OLVMNOGESA-N 3-hydroxy-(3-α,5-α)-Pregnane-11,20-dione Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O DUHUCHOQIDJXAT-OLVMNOGESA-N 0.000 claims description 6
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 6
- BWOPOAOBPJWDBF-UHFFFAOYSA-N 1,11-bis-epi-artesin Natural products C1CC2(C)C(O)CCC(C)=C2C2C1C(C)C(=O)O2 BWOPOAOBPJWDBF-UHFFFAOYSA-N 0.000 claims description 5
- USPYDUPOCUYHQL-VEVMSBRDSA-N 5beta-dihydrodeoxycorticosterone Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CC[C@@H]21 USPYDUPOCUYHQL-VEVMSBRDSA-N 0.000 claims description 5
- BWOPOAOBPJWDBF-UWSPEPLBSA-N Artesin Natural products O[C@@H]([C@]1(C)CC2)CCC(C)=C1[C@@H]1[C@@H]2[C@H](C)C(=O)O1 BWOPOAOBPJWDBF-UWSPEPLBSA-N 0.000 claims description 5
- PGTVWKLGGCQMBR-FLBATMFCSA-N Ganaxolone Chemical compound C([C@@H]1CC2)[C@](C)(O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 PGTVWKLGGCQMBR-FLBATMFCSA-N 0.000 claims description 5
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 claims description 5
- 229950006567 ganaxolone Drugs 0.000 claims description 5
- NCGLTZSBTFVVAW-KNXRZYMVSA-N minaxolone Chemical compound C1[C@@H](N(C)C)[C@@H]2[C@@]3(C)C[C@H](OCC)[C@@H](O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](C(C)=O)[C@]21C NCGLTZSBTFVVAW-KNXRZYMVSA-N 0.000 claims description 5
- 229960004798 minaxolone Drugs 0.000 claims description 5
- 159000000000 sodium salts Chemical class 0.000 claims description 5
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims description 5
- CYKYBWRSLLXBOW-GDYGHMJCSA-N 5-alpha-THDOC Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CC[C@H]21 CYKYBWRSLLXBOW-GDYGHMJCSA-N 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 208000005809 status epilepticus Diseases 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- 208000007848 Alcoholism Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000001914 Fragile X syndrome Diseases 0.000 claims description 2
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 2
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims description 2
- 201000009916 Postpartum depression Diseases 0.000 claims description 2
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims description 2
- 206010071350 Seizure cluster Diseases 0.000 claims description 2
- 206010043994 Tonic convulsion Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 208000028502 clonic seizure Diseases 0.000 claims description 2
- 201000009028 early myoclonic encephalopathy Diseases 0.000 claims description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 208000028500 tonic seizure Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 208000014060 Niemann-Pick disease Diseases 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 22
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 2
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- 102000001584 Neurotransmitter-gated ion-channels Human genes 0.000 description 1
- 108050009804 Neurotransmitter-gated ion-channels Proteins 0.000 description 1
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008587 neuronal excitability Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 108010085082 sigma receptors Proteins 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000033556 type C1 Niemann-Pick disease Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018131186A JP6966981B2 (ja) | 2012-11-30 | 2018-07-11 | ステロイドの抗痙攣活性 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261732252P | 2012-11-30 | 2012-11-30 | |
| US61/732,252 | 2012-11-30 | ||
| PCT/US2013/072351 WO2014085668A1 (en) | 2012-11-30 | 2013-11-27 | Anticonvulsant activity of steroids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018131186A Division JP6966981B2 (ja) | 2012-11-30 | 2018-07-11 | ステロイドの抗痙攣活性 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016501876A JP2016501876A (ja) | 2016-01-21 |
| JP2016501876A5 true JP2016501876A5 (enExample) | 2017-01-05 |
Family
ID=50828483
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545458A Withdrawn JP2016501876A (ja) | 2012-11-30 | 2013-11-27 | ステロイドの抗痙攣活性 |
| JP2018131186A Active JP6966981B2 (ja) | 2012-11-30 | 2018-07-11 | ステロイドの抗痙攣活性 |
| JP2021108255A Active JP7744166B2 (ja) | 2012-11-30 | 2021-06-30 | ステロイドの抗痙攣活性 |
| JP2023125962A Pending JP2023133494A (ja) | 2012-11-30 | 2023-08-02 | ステロイドの抗痙攣活性 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018131186A Active JP6966981B2 (ja) | 2012-11-30 | 2018-07-11 | ステロイドの抗痙攣活性 |
| JP2021108255A Active JP7744166B2 (ja) | 2012-11-30 | 2021-06-30 | ステロイドの抗痙攣活性 |
| JP2023125962A Pending JP2023133494A (ja) | 2012-11-30 | 2023-08-02 | ステロイドの抗痙攣活性 |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US20150313915A1 (enExample) |
| EP (2) | EP2925327B1 (enExample) |
| JP (4) | JP2016501876A (enExample) |
| AU (4) | AU2013352141B2 (enExample) |
| DK (1) | DK2925327T3 (enExample) |
| ES (1) | ES2973320T3 (enExample) |
| WO (1) | WO2014085668A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120107533A (ko) | 2005-11-28 | 2012-10-02 | 마리누스 파마슈티컬스 | ｇａｎａｘｏｌｏｎｅ 제형, 이의 제조방법 및 용도 |
| US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| HRP20192348T1 (hr) * | 2012-01-23 | 2020-03-20 | Sage Therapeutics, Inc. | Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil eter beta-ciklodekstrina |
| WO2014028398A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| KR102121633B1 (ko) | 2012-08-21 | 2020-06-10 | 세이지 테라퓨틱스, 인크. | 간질 또는 간질지속 상태를 치료하는 방법 |
| DK2925327T3 (da) | 2012-11-30 | 2024-03-25 | Univ California | Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression |
| EP2986623B1 (en) | 2013-04-17 | 2018-11-07 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) * | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| CN107206097A (zh) * | 2014-11-18 | 2017-09-26 | 皮克萨尔比奥公司 | 用于治疗急性、术后或慢性疼痛的组合物及其使用方法 |
| HUE049014T2 (hu) | 2014-11-27 | 2020-09-28 | Sage Therapeutics Inc | Készítmények és módszerek a központi idegrendszer rendellenességeinek kezelésére |
| WO2016127170A1 (en) * | 2015-02-06 | 2016-08-11 | Marinus Pharmaceuticals, Inc. | Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders |
| EP3280420B1 (en) * | 2015-04-10 | 2024-03-27 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| MA45276A (fr) * | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
| AU2016295138B2 (en) * | 2015-07-17 | 2021-11-04 | Ovid Therapeutics Inc. | Methods of treating developmental disorders with gaboxadol |
| KR20180052611A (ko) | 2015-08-18 | 2018-05-18 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 영상화 및 치료 용도를 위한 니트록사이드 함유 아밀로이드 결합 제제 |
| EP3362042A1 (en) | 2015-10-16 | 2018-08-22 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| CA3017172C (en) * | 2016-03-08 | 2023-03-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10858338B2 (en) | 2016-03-15 | 2020-12-08 | The Regents Of The University Of California | Inhibitors for soluble epoxide hydrolase (SEH) and fatty acid amide hydrolase (FAAH) |
| CN119112906A (zh) | 2016-08-11 | 2024-12-13 | 奥维德医疗公司 | 用于治疗癫痫性紊乱的方法和组合物 |
| IL315950A (en) | 2016-08-23 | 2024-11-01 | Sage Therapeutics Inc | 19-NOR C3, 3-Dimuter C21-N-Pyrazolyl Steroid Crystalline |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| EP3678659B1 (en) * | 2017-09-05 | 2025-12-17 | Eagle Pharmaceuticals, Inc. | Methods of using dantrolene to treat exposure to a neurotoxic agent |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| EP3946358A4 (en) * | 2019-04-05 | 2022-12-28 | The Regents of The University of California | ALLOPREGNANOLON COMPOSITIONS AND USES THEREOF |
| SG11202112111WA (en) | 2019-05-10 | 2021-11-29 | Brii Biosciences Inc | Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof |
| JP7754799B2 (ja) | 2019-08-05 | 2025-10-15 | マリナス ファーマシューティカルズ， インコーポレイテッド | てんかん重積状態の治療に使用するためのガナキソロン |
| EP4072559A4 (en) | 2019-12-06 | 2023-06-21 | Marinus Pharmaceuticals, Inc. | GANAXOLONE FOR USE IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX |
| PE20221911A1 (es) | 2020-03-25 | 2022-12-23 | Sage Therapeutics Inc | Uso de agentes para el tratamiento de condiciones respiratorias |
| US11969434B1 (en) | 2022-08-29 | 2024-04-30 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
| US12208103B1 (en) * | 2021-05-07 | 2025-01-28 | Lipocine Inc. | Compositions and methods for treating CNS disorders |
| US12005185B2 (en) | 2021-12-17 | 2024-06-11 | Belhaven BioPharma Inc. | Medical counter measures including dry powder formulations and associated methods |
| US12186327B2 (en) | 2022-08-29 | 2025-01-07 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3865939A (en) | 1973-02-23 | 1975-02-11 | Procter & Gamble | Edible oils having hypocholesterolemic properties |
| SE8600632D0 (sv) | 1986-02-13 | 1986-02-13 | Kabivitrum Ab | Novel pharmaceutical composition |
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
| US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5497763A (en) | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
| DE69435286D1 (de) | 1993-05-24 | 2010-05-20 | Purdue Pharma Ltd | Verfahren und zusammensetzungen zum hervorrufen von schlaf |
| DE69518509T2 (de) | 1994-02-14 | 2001-04-19 | Euro-Celtique S.A., Luxemburg/Luxembourg | Androstane und pregnane zur allosterischen modulation des gaba-rezeptors |
| WO1996016076A1 (en) | 1994-11-23 | 1996-05-30 | Cocensys, Inc. | Androstane and pregnane series for allosteric modulation of gaba receptor |
| US6780853B1 (en) | 1995-06-06 | 2004-08-24 | Euro-Celtique S.A. | Neuroactive steroids of the androstane and pregnane series |
| CZ394197A3 (cs) | 1995-06-06 | 1998-06-17 | Cocensys, Inc. | Neuroaktivní steroidy androstanové a pregnanové řady |
| EP0840612A1 (en) | 1995-07-24 | 1998-05-13 | Trustees Of Boston University | Inhibition of nmda receptor activity by pregnenolone sulfate derivatives |
| US7630757B2 (en) | 1997-01-06 | 2009-12-08 | Flint Hills Scientific Llc | System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject |
| US6245757B1 (en) | 1997-10-03 | 2001-06-12 | Research Corporation Technologies, Inc. | Use of progestins to treat ischemic event |
| JP3877961B2 (ja) * | 1998-03-11 | 2007-02-07 | ベクストルム，トルビエーン | Ｃｎｓ疾患の治療におけるエピアロプレグナノロン |
| EP1175390B1 (en) | 1999-04-05 | 2005-02-02 | Emisphere Technologies, Inc. | Disodium salts, monohydrates, and ethanol solvates |
| US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| US20020072509A1 (en) | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| US6737043B2 (en) | 2001-05-24 | 2004-05-18 | Alexza Molecula Delivery Corporation | Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
| EP1392260A2 (en) | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of benzodiazepines through an inhalation route |
| US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
| JP2003063965A (ja) | 2001-06-13 | 2003-03-05 | Otsuka Pharmaceut Factory Inc | 注射用シロスタゾール水性製剤 |
| US8354438B2 (en) | 2001-08-08 | 2013-01-15 | Michael Chez | Neurological functions |
| WO2004019953A1 (en) | 2002-08-28 | 2004-03-11 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment methods |
| US7781421B2 (en) | 2003-05-29 | 2010-08-24 | Washington University | Neuroactive 13, 24-cyclo-18, 21-dinorcholanes and structurally related pentacyclic steriods |
| US7816074B2 (en) | 2003-07-31 | 2010-10-19 | The Research Foundation Of State University Of New York | α4 β2 δGABA-A receptors as a strategy for PMS and alcoholism |
| GB0321607D0 (en) | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
| US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
| WO2006034196A1 (en) | 2004-09-17 | 2006-03-30 | Lifelike Biomatic Inc. | Compositions for enhancing memory and methods therefor |
| US8604011B2 (en) | 2004-09-27 | 2013-12-10 | The Regents Of The University Of California | Therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| EA013433B1 (ru) | 2005-02-15 | 2010-04-30 | Элан Фарма Интернэшнл Лтд. | Аэрозольные и впрыскиваемые рецептуры лекарственных препаратов бензодиазепина, состоящего из наночастиц |
| WO2006102644A2 (en) | 2005-03-24 | 2006-09-28 | Emory University | Methods for the treatment of central nervous system injury via a tapered administration of progesterone |
| JP2008538748A (ja) | 2005-04-07 | 2008-11-06 | ハイシアム， インコーポレイテッド | 不安、物質乱用及び依存の予防のための改良型方法及び組成物 |
| US20110319386A1 (en) | 2005-08-26 | 2011-12-29 | Braincells Inc. | Neurogenesis by muscarinic receptor modulation |
| KR20120107533A (ko) * | 2005-11-28 | 2012-10-02 | 마리누스 파마슈티컬스 | ｇａｎａｘｏｌｏｎｅ 제형, 이의 제조방법 및 용도 |
| US20070287931A1 (en) | 2006-02-14 | 2007-12-13 | Dilorenzo Daniel J | Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders |
| US20080026918A1 (en) * | 2006-07-27 | 2008-01-31 | Michael Lemke | Athletic training device with multi-directional movement |
| US20090239942A1 (en) | 2006-09-15 | 2009-09-24 | Cloyd James C | Topiramate Compositions and Methods of Making and Using the Same |
| US20090074677A1 (en) | 2007-01-08 | 2009-03-19 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| US20090203658A1 (en) | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| US7813811B2 (en) | 2007-02-08 | 2010-10-12 | Neuropace, Inc. | Refillable reservoir lead systems |
| US20080243022A1 (en) | 2007-03-30 | 2008-10-02 | Donnett James G | Seizure prediction using brain signal telemetry |
| US8530463B2 (en) | 2007-05-07 | 2013-09-10 | Hale Biopharma Ventures Llc | Multimodal particulate formulations |
| EP2167098B1 (en) | 2007-06-11 | 2018-09-05 | University Of Southern California | Allopregnanolone in a method for enhancing neurological function (alzheimer disease) |
| JP5663303B2 (ja) * | 2007-06-15 | 2015-02-04 | リサーチ トライアングル インスティテュート | Ｇａｂａレセプタークロライドイオノフォアの潜在的アロステリック調節特性を有するアンドロスタンステロイドおよびプレグナンステロイド |
| GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
| EP2175886A1 (en) | 2007-06-28 | 2010-04-21 | CNSBio Pty Ltd | Combination methods and compositions for treatment of neuropathic pain |
| US9788744B2 (en) | 2007-07-27 | 2017-10-17 | Cyberonics, Inc. | Systems for monitoring brain activity and patient advisory device |
| US20100297181A1 (en) | 2007-12-26 | 2010-11-25 | Eisai R&D Management Co., Ltd. | AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ |
| US20090198145A1 (en) | 2008-02-06 | 2009-08-06 | Chow Harrison | Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep |
| US8729070B2 (en) | 2008-02-20 | 2014-05-20 | Targia Pharmaceuticals | CNS pharmaceutical compositions and methods of use |
| ES2617873T3 (es) | 2008-10-10 | 2017-06-20 | Vm Discovery, Inc. | Composiciones y métodos para tratar trastornos de alcoholismo, dolor y otras enfermedades |
| CN102300566A (zh) | 2008-11-30 | 2011-12-28 | O·扎查尔 | 血管收缩剂的皮肤应用 |
| EP2369986A4 (en) | 2008-12-23 | 2013-08-28 | Neurovista Corp | BRAIN STATUS ANALYSIS BASED ON SELECTED ANTI-BREAKING CHARACTERISTICS AND CLINICAL MANIFESTATIONS |
| US20110306579A1 (en) | 2009-01-30 | 2011-12-15 | Emory University | Methods of neuroprotection using neuroprotective steroids and a vitamin d |
| ES2525257T3 (es) * | 2009-02-25 | 2014-12-19 | Supratek Pharma, Inc. | Composiciones de ciclopolisacárido y de bendamustina |
| WO2010107922A1 (en) | 2009-03-17 | 2010-09-23 | Duke University | Neuroactive steroid compositions and methods of use for lowering cholesterol |
| US20110152840A1 (en) | 2009-12-23 | 2011-06-23 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| HRP20171699T1 (hr) | 2010-01-21 | 2018-01-26 | Drawbridge Pharmaceuticals Pty Ltd. | Formulacija anestetika |
| CA2816806A1 (en) | 2010-11-03 | 2012-05-10 | Sanofi-Aventis Deutschland Gmbh | Needle cannula containing medicament |
| US20130309306A1 (en) | 2010-12-01 | 2013-11-21 | The Regents Of The University Of California | Intrapulmonary benzodiazepine for the treatment and prevention of seizures |
| US9084797B2 (en) | 2011-05-23 | 2015-07-21 | Besins Healthcare Luxembourg Sarl | Progesterone treatment for improving sleep quality |
| KR20130002292A (ko) | 2011-06-28 | 2013-01-07 | 주식회사 비보존 | 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도 |
| WO2013019711A2 (en) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS |
| CN107936076B (zh) | 2011-09-08 | 2021-10-15 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| AU2012323888A1 (en) | 2011-10-14 | 2014-05-29 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| KR20140098811A (ko) | 2011-11-29 | 2014-08-08 | 가부시키가이샤 아미노 압 가가쿠 | 신경 및/또는 인지 기능에 대한 유익한 효과를 갖는 비세닌-2를 포함하는 조성물 |
| HRP20192348T1 (hr) * | 2012-01-23 | 2020-03-20 | Sage Therapeutics, Inc. | Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil eter beta-ciklodekstrina |
| WO2013188792A2 (en) | 2012-06-15 | 2013-12-19 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2014028398A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| KR102121633B1 (ko) | 2012-08-21 | 2020-06-10 | 세이지 테라퓨틱스, 인크. | 간질 또는 간질지속 상태를 치료하는 방법 |
| US9757391B2 (en) | 2012-11-09 | 2017-09-12 | Goodchild Investments Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| DK2925327T3 (da) | 2012-11-30 | 2024-03-25 | Univ California | Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression |
| WO2014108808A2 (en) | 2013-01-09 | 2014-07-17 | Henry James Lorne | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| KR20180054796A (ko) | 2015-10-14 | 2018-05-24 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 베타 세포 복제 및/또는 생존의 향상 |
| CA3017172C (en) | 2016-03-08 | 2023-03-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US20180050005A1 (en) | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Concentrated Solution of 17-Hydroxydocosahexaenoic Acid |
| US20180050107A1 (en) | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Neurosteroid compositions and methods of use thereof |
| AU2017324262B2 (en) | 2016-09-07 | 2023-06-22 | Glia, Llc | Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
-
2013
- 2013-11-27 DK DK13857993.3T patent/DK2925327T3/da active
- 2013-11-27 AU AU2013352141A patent/AU2013352141B2/en active Active
- 2013-11-27 JP JP2015545458A patent/JP2016501876A/ja not_active Withdrawn
- 2013-11-27 EP EP13857993.3A patent/EP2925327B1/en active Active
- 2013-11-27 EP EP23211768.9A patent/EP4335505A3/en active Pending
- 2013-11-27 WO PCT/US2013/072351 patent/WO2014085668A1/en not_active Ceased
- 2013-11-27 US US14/646,886 patent/US20150313915A1/en not_active Abandoned
- 2013-11-27 ES ES13857993T patent/ES2973320T3/es active Active
-
2017
- 2017-06-25 US US15/632,360 patent/US20180133229A1/en not_active Abandoned
-
2018
- 2018-03-09 US US15/917,245 patent/US10251894B2/en active Active
- 2018-07-04 AU AU2018204865A patent/AU2018204865B2/en active Active
- 2018-07-11 JP JP2018131186A patent/JP6966981B2/ja active Active
-
2019
- 2019-01-07 US US16/241,877 patent/US20190142845A1/en not_active Abandoned
-
2020
- 2020-03-17 AU AU2020201919A patent/AU2020201919B2/en active Active
- 2020-10-06 US US17/064,517 patent/US20210100817A1/en not_active Abandoned
-
2021
- 2021-06-30 JP JP2021108255A patent/JP7744166B2/ja active Active
-
2022
- 2022-05-03 AU AU2022202943A patent/AU2022202943B2/en active Active
-
2023
- 2023-08-02 JP JP2023125962A patent/JP2023133494A/ja active Pending
-
2024
- 2024-02-14 US US18/442,086 patent/US20240197754A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501876A5 (enExample) | ||
| JP7566961B2 (ja) | 静注用ガナキソロン製剤ならびにてんかん重積状態および他の発作性障害の治療におけるその使用 | |
| JP2015527371A5 (enExample) | ||
| US8349820B2 (en) | Use of estradiol valerate or 17β-estradiol in combination with dienogest for oral therapy to maintain and/or increase feminine libido | |
| JP2018193377A (ja) | ステロイドの抗痙攣活性 | |
| CN1270718C (zh) | 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用 | |
| EP3191101A1 (en) | Neuroactive steroids, compositions, and uses thereof | |
| WO2018169798A9 (en) | Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers | |
| WO2014071449A1 (en) | Neuroactive steroids and their use to facilitate neuroprotection | |
| JP2012502909A5 (enExample) | ||
| BR112012032076A2 (pt) | composição farmacêutica, e, métodos para tratar um paciente que está sofrendo de um distúrbio e de uma doença neurodegenerativa | |
| CN1443078A (zh) | 用于人的睾酮酯制剂 | |
| JP2016517421A5 (enExample) | ||
| CA2988262A1 (en) | Neuroactive steroid solutions and their methods of use | |
| Nalamolu et al. | Stem cell treatment improves post stroke neurological outcomes: a comparative study in male and female rats | |
| BR112019007448A2 (pt) | método de administrar um neuroesteróide para provocar surto- supressão eletroencefalográfica (eeg) | |
| WO2013192610A3 (en) | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | |
| Cowie et al. | Anti-emetic doses of dexamethasone suppress cortisol response in laparoscopic cholecystectomy | |
| Van Rossum et al. | Fingolimod-induced asthma deterioration in a patient with relapsing-remitting multiple sclerosis | |
| Makri et al. | Sugammadex, a promising reversal drug. A review of clinical trials | |
| Shafiey et al. | Effect of Budesonide and Systemic Corticosteroids on Hospital Admissions and Length of Stay: A Meta-analysis | |
| Regmi et al. | Comparison of Propofol-Ketamine Combination with Propofol-Butorphanol Combination for Total Intravenous Anaesthesia on Short Surgical Procedures | |
| US20230149425A1 (en) | Process and therapeutic composition for treating and preventing severe injection site reactions | |
| US20190183956A1 (en) | Use of a clove oil fraction | |
| JP5909941B2 (ja) | ステロイド性抗炎症薬含有外用剤 |